Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl; Bruce Strober; Alan Menter; Kenneth B. Gordon; Jolanta Węgłowska; L. Puig; Kim Papp; Lynda Spelman; Darryl Toth; Francisco A. Kerdel; April W. Armstrong; Georg Stingl; Alexa B. Kimball; H. Bachelez; Jashin J. Wu; Jeffrey Crowley; Richard G. Langley; Tomasz Blicharski; C. Paul; J.‐P. Lacour; Stephen K. Tyring; Leon Kircik; Sergio Chimenti; Kristina Callis Duffin; Jerry Bagel; John Koo; Gary Aras; Joanne Li; Wenjie Song; Cassandra E. Milmont; Yifei Shi; Ngozi Erondu; Paul Klekotka; Brian L. Kotzin; Ajay Nirula

doi:10.1056/nejmoa1503824

Abstract

This is the authors' abstract. We don't add key points for this paper.

Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lebwohl et al. (2015) studied this question.

synapsesocial.com/papers/69d76b0fb1cb92dd1bb8b0f4 https://doi.org/10.1056/nejmoa1503824

View Full Paper

Ask AI

Bookmark

Share

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Abstract

Ask about this paper

Discussion

Cite This Study

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading